Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced ADESOS Phase 2b results selected as a late-breaking oral ...
7h
Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...
Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...
The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...
A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...
The oral drug, Zenrelia, is to control pruritus, or itching, associated with allergic dermatitis and control of atopic ...
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback